Cargando…
Efficacy and Safety of Tiropramide in the Treatment of Patients With Irritable Bowel Syndrome: A Multicenter, Randomized, Double-blind, Non-inferiority Trial, Compared With Octylonium
BACKGROUND/AIMS: Antispasmodics such as octylonium are widely used to manage irritable bowel syndrome (IBS) symptoms. However, the efficacy and safety of another antispasmodic, tiropramide, remain uncertain. We aimed to evaluate the efficacy and safety of tiropramide compared with octylonium in pati...
Autores principales: | Lee, Kang Nyeong, Lee, Oh Young, Choi, Myung-Gyu, Sohn, Chong Il, Huh, Kyu Chan, Park, Kyung Sik, Kwon, Joong Goo, Kim, Nayoung, Rhee, Poong-Lyul, Myung, Seung-Jae, Lee, Joon Seong, Lee, Kwang Jae, Park, Hyojin, Lee, Yong Chan, Choi, Suck Chei, Jung, Hye-Kyung, Jee, Sam Ryong, Choi, Chang Hwan, Kim, Gwang Ha, Park, Moo In, Sung, In Kyung |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Korean Society of Neurogastroenterology and Motility
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3895597/ https://www.ncbi.nlm.nih.gov/pubmed/24466452 http://dx.doi.org/10.5056/jnm.2014.20.1.113 |
Ejemplares similares
-
Efficacy and Safety of DWJ1252 Compared With Gasmotin in the Treatment of Functional Dyspepsia: A Multicenter, Randomized, Double-blind, Active-controlled Study
por: Park, Jin Hwa, et al.
Publicado: (2021) -
Efficacy of DA-9701 (Motilitone) in Functional Dyspepsia Compared to Pantoprazole: A Multicenter, Randomized, Double-blind, Non-inferiority Study
por: Jung, Hye-Kyung, et al.
Publicado: (2016) -
The Effect of Tegaserod on Symptoms and Quality of Life in Korean Women with Irritable Bowel Syndrome with Constipation
por: Kim, Yong Sung, et al.
Publicado: (2010) -
Randomized controlled trial to evaluate the efficacy and safety of fexuprazan compared with esomeprazole in erosive esophagitis
por: Lee, Kang Nyeong, et al.
Publicado: (2022) -
A Randomized, Double-Blind, Active-Control, Noninferiority, Multicenter, Phase 4 Study to Evaluate the Efficacy and Safety of Esomeprazole/Sodium Bicarbonate 20/800 mg in Patients with Nonerosive Gastroesophageal Reflux Disease
por: Park, Su Hyun, et al.
Publicado: (2023)